Daridorexant 50 mg met the primary endpoint of change from baseline in subjective total sleep time at Day 28 versus placebo (p<0.0001) in a South Korea Phase 3 trial, and achieved significant improvements on subjective latency to sleep onset and subjective wake after sleep onset (both p<0.0001). Safety was placebo-like, with treatment-emergent adverse events reported in 13.41% on daridorexant versus 14.81% on placebo over the 28-day, once-daily regimen. Nxera reported positive top-line results from a multicenter, randomized, double-blind, placebo-controlled Phase 3 study in adult and elderly patients with insomnia in South Korea and plans to submit a marketing authorization application in Q1 2026, targeting approval in Q1 2027. Daridorexant, a dual orexin receptor antagonist, is already approved in Japan as QUVIVIQ under a commercialization arrangement, while the molecule is marketed by other partners in the US, Europe, China, and Hong Kong. The Korean study used a single 50 mg dose arm versus placebo for 28 days and relied on patient-reported sleep endpoints consistent with prior global programs in the class. Strategically, this is a regional consolidation move that extends Nxera’s orexin-franchise footprint across APAC with a locally generated dataset tailored for Ministry of Food and Drug Safety expectations. Running a dedicated Korean Phase 3 using subjective endpoints and a short treatment horizon trades depth for speed: it reduces site burden, diary compliance demands, and cost, while creating a clean bridge to established global evidence for longer-term safety and next-morning performance. The single-dose design simplifies positioning but forgoes dose-ranging optionality that some prescribers value. The 2026 filing timeline, despite top-line success now, signals parallel workstreams on CMC localization, labeling harmonization, and pre-alignment with reimbursement bodies to avoid a post-approval access gap. For sites and CROs, the trial design underscores an operational template that has become standard in insomnia: eCOA-driven diaries, minimal in-clinic procedures, and broad inclusion of older adults. That model enables faster enrollment and lower monitoring intensity, which is attractive amid staffing constraints, but places a premium on data quality controls for subjective measures. Regulators will see familiar anchors—sTST, sLSO, sWASO—paired with a benign short-term safety profile, while payers will look for signals that translate into daytime functioning and fewer residual effects, especially in a population skewing older. For sponsors, the move exemplifies a regional execution strategy built on partitioned commercialization rights and local efficacy packages, requiring tight coordination on pharmacovigilance, supply chain, and medical affairs across Japan, Korea, and China. Competitive dynamics in Korea already include other DORAs and entrenched hypnotics, positioning daridorexant to compete on tolerability, next-day profile, and dosing convenience. Next, attention turns to the completeness of the Korean submission package: durability beyond 28 days, driving and next-morning impairment, abuse liability, and interactions with CNS depressants will be closely examined, with potential implications for scheduling and prescribing restrictions. Head-to-head data versus incumbents are not required for approval but could become important in HIRA negotiations and formulary placement given the crowded class. Expect post-approval commitments or local extensions to generate longer-term safety and real-world evidence, where decentralized follow-up and claims analytics could be leveraged. Execution risk sits in reimbursement timing and label nuances relative to US/EU/Japan; success will hinge on demonstrating functional benefits that matter to clinicians and payers while maintaining the class’s tolerability narrative. Watch for early dialogue outcomes with MFDS and HIRA, any dose flexibility considerations, and whether Nxera pursues broader sleep-disorder indications to expand the franchise once Korea is secured.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
